Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer
Umberto Capitanio, MD
Umberto Capitanio, MD, FEBU, Department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.
In the United States, sunitinib (Sutent) is now approved for the adjuvant treatment of this population. In Europe however, guidelines do not recommend the use of adjuvant therapy due to conflicting published results.